These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10378514)

  • 21. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
    Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
    J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.
    Cinque P; Nebuloni M; Santovito ML; Price RW; Gisslen M; Hagberg L; Bestetti A; Vago G; Lazzarin A; Blasi F; Sidenius N
    Ann Neurol; 2004 May; 55(5):687-94. PubMed ID: 15122709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality.
    Wittenhagen P; Kronborg G; Weis N; Nielsen H; Obel N; Pedersen SS; Eugen-Olsen J
    Clin Microbiol Infect; 2004 May; 10(5):409-15. PubMed ID: 15113317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
    Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
    Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.
    Lutz V; Reuning U; Krüger A; Luther T; von Steinburg SP; Graeff H; Schmitt M; Wilhelm OG; Magdolen V
    Biol Chem; 2001 May; 382(5):789-98. PubMed ID: 11517932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
    Gong SJ; Rha SY; Chung HC; Yoo NC; Roh JK; Yang WI; Lee KS; Min JS; Kim BS; Chung HC
    Int J Mol Med; 2000 Sep; 6(3):301-5. PubMed ID: 10934293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report.
    Cole LA; Tanaka A; Kim GS; Park SY; Koh MW; Schwartz PE; Chambers JT; Nam JH
    Gynecol Oncol; 1996 Feb; 60(2):264-70. PubMed ID: 8631549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer.
    de Bock CE; Wang Y
    Med Res Rev; 2004 Jan; 24(1):13-39. PubMed ID: 14595671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma].
    Li YJ; Zheng BZ; Zhou ZL
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):57-9. PubMed ID: 14981816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer.
    Selleri C; Montuori N; Ricci P; Visconte V; Baiano A; Carriero MV; Rotoli B; Rossi G; Ragno P
    Cancer Res; 2006 Nov; 66(22):10885-90. PubMed ID: 17108125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary cyclic GMP after treatment of gynecological cancer. A prognostic marker of clinical outcome.
    Orbo A; Hanevik M; Jaeger R; Van Heusden S; Sager G
    Anticancer Res; 2007; 27(4C):2591-6. PubMed ID: 17695420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble urokinase plasminogen activator receptor during allogeneic stem cell transplantation.
    Haastrup E; Andersen J; Ostrowski SR; Høyer-Hansen G; Jacobsen N; Heilmann C; Ullum H; Müller K
    Scand J Immunol; 2011 Apr; 73(4):325-9. PubMed ID: 21223347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
    D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
    Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability.
    Olson FJ; Thurison T; Ryndel M; Høyer-Hansen G; Fagerberg B
    Clin Biochem; 2010 Jan; 43(1-2):124-30. PubMed ID: 19822140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
    Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
    J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
    Huang M; Mazar AP; Parry G; Higazi AA; Kuo A; Cines DB
    Acta Crystallogr D Biol Crystallogr; 2005 Jun; 61(Pt 6):697-700. PubMed ID: 15930623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome.
    Ostrowski SR; Ullum H; Goka BQ; Høyer-Hansen G; Obeng-Adjei G; Pedersen BK; Akanmori BD; Kurtzhals JA
    J Infect Dis; 2005 Apr; 191(8):1331-41. PubMed ID: 15776381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of hormones on uPA, PAI-1 and suPAR from cultured endometrial and ovarian endometriotic stromal cells.
    Guan YM; Carlberg M; Bruse C; Carlström K; Bergqvist A
    Acta Obstet Gynecol Scand; 2002 May; 81(5):389-97. PubMed ID: 12027810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
    Werle B; Kotzsch M; Lah TT; Kos J; Gabrijelcic-Geiger D; Spiess E; Schirren J; Ebert W; Fiehn W; Luther T; Magdolen V; Schmitt M; Harbeck N
    Anticancer Res; 2004; 24(6):4147-61. PubMed ID: 15736466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.